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In recent years one of the more alarming aspects of clinical microbiology has been the
dramatic increase in the incidence of resistance to antibacterial agents among pathogens
causing nosocomial as well as community-acquired infections. There are profound
geographic differences in the incidence of resistance among pathogens of the respiratory
tract, only some of which can be explained by the local use of antibiotics. A high
percentage of Moraxella catarrhalis strains produce b-lactamase and are thus resistant
to many b-lactam antibiotics. In contrast, b-lactamase production among strains of
Haemophilus inﬂuenzae rarely reaches more than 30% around the world. Methicillin-
resistance in Staphylococcus aureus is a common and increasing problem in hospitals but
its extent varies both locally and nationally. Resistance is usually associatedwith the local
spread of resistant strains. High standards of hygiene in hospitals can prevent the spread
of such strains but once established they can be difﬁcult to eradicate. Although Strepto-
coccus pyogenes remains highly susceptible to penicillins, even after many decades of their
use, resistance to macrolides has occurred. This resistance can rise and fall. Although the
increase of macrolide resistance in S. pyogenes can often be associated with an increase in
the use of these drugs, this is not always so. In some cases it has been shown to be caused
by the spread of one or more resistant clones. Eradication of these clones can reduce the
level of resistance markedly. Resistance to both macrolides and penicillins among strains
of Streptococcus pneumoniae is seen world-wide but is highly variable from country to
country. Local habits of drug usage may play a part. In Italy, for example, there
is preference for the use of parenteral third-generation cephalosporins for some
severe infections and there is a corresponding low level of penicillin-resistance among
pneumococci.
INTRODUCTION
In recent years one of the more alarming aspects of
clinical microbiology has been the dramatic
increase in the incidence of antibacterial resistance
among pathogens causing nosocomial as well as
community-acquired infections. This increase in
resistance is now a global problem, with no coun-
try remaining immune to its impact. All major
bacterial pathogens have now acquired resistance
to at least one drug and in some cases, they have
become resistant to many drugs.
The situation regarding some important patho-
gens is discussed in this article. It will be noted
that there is no uniform picture, in one country
resistance may be high in a particular pathogen to
a particular drug, but not in that pathogen to
another drug and not to that drug in all pathogens.
The reasons for these variations are often not
evident.
RESISTANCE VARIES GLOBALLY
Resistance to antimicrobial drugs is known to vary
profoundly, depending on the geographic loca-
tion, the pathogen and the drug. An additional
contributing factor may be local variations in the
use of antibacterial agents. A number of common
community-acquired infections are caused by
pathogens that are now frequently resistant to
one or more antibacterial agents. These include
the respiratory tract pathogens Streptococcus pneu-
moniae, Streptococcus pyogenes and Haemophilus
inﬂuenzae, as well as organisms causing a variety
of other infections, such as Escherichia coli,Neisseria
gonorrhoeae, Salmonella spp., Staphylococcus aureus
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and Mycobacterium tuberculosis. Some pathogens
are more commonly associated with hospital-
acquired infections and many of these have also
acquired resistance to one or more drugs. The
species most commonly associated with resistance
include S. pneumoniae, S. aureus, strains of Pseudo-
monas, Enterococcus and a wide range of entero-
bacteria.
Two species with a particularly high rate of
resistance globally are S. aureus and Moraxella
catarrhalis. Resistance to penicillin among strains
of S. aureus has reached over 85% world-wide (see
below) and over 90% of M. catarrhalis strains are
resistant to all aminopenicillins. In contrast to
these pathogens, b-lactamase production in strains
of H. inﬂuenzae is spreading relatively slowly and
it is rare to ﬁnd more than 30% of strains resistant
to the aminopenicillins [1]. Local differences can
be identiﬁed, with a sharp increase in resistance
to amoxicillin occurring in Italy, up from 5% in
1997 to 16% in 1999. Of note is the lack of resist-
ance in H. inﬂuenzae to the other major groups of
widely used b-lactam antibiotics, for example
the third-generation cephalosporins, which do
not have a recognized breakpoint for resistance
(Figure 1).
It is interesting to speculate on the forces inﬂu-
encing these patterns of resistance. A factor inﬂu-
encing the high resistance among staphylococci
and Moraxella could be the constant and ubiqui-
tous selective pressure of the commonly used
penicillins, but both Haemophilus and S. pyogenes
have been exposed to penicillins for many years
without a uniform development of resistance.
Invasive genetic elements may be a partial
explanation.
STREPTOCOCCUS PYOGENES
The situation with S. pyogenes varies considerably,
with resistance frequently being reported to
macrolides but not to b-lactams. Despite the pro-
longed use of penicillins and other b-lactams over
several decades, S. pyogenes remains highly sus-
ceptible to this class of antibiotics world-wide. In
sharp contrast to this, resistance to macrolides is
common but variable. In most countries it remains
below 5% but major outbreaks of resistance to
macrolides have occurred in some countries; often
this can be linked to the spread of a particular
clone or to high usage of macrolides.
Resistance to macrolides in S. pyogenes was ﬁrst
reported from the UK as long ago as 1959 and
subsequently from many other countries. In some
countries, high rates of resistance have been
reported, including Australia, Finland, Sweden,
Taiwan, Japan and Italy. The emergence of resis-
tance can be surprisingly rapid [2,3].
Mechanisms of resistance to macrolides
There are two major mechanisms by which
S. pyogenes develop resistance to macrolides and
they result in three phenotypes [4]. In two of the
Figure 1 Prevalence of b-lactamase-
producing strains of Haemophilus
influenzae. Data adapted from Schito
et al. [1] (Alexander Project 1998).
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phenotypes the target site is modiﬁed and in the
other phenotype the antibiotic is pumped out of
the bacterial cell (efﬂux mechanism). The site of
action of macrolides is on the ribosome, and if this
is methylated the conformation is changed, lead-
ing to a reduction in binding of the antibiotic,
which is thus rendered ineffective. This target
alteration can be either a constitutive or an indu-
cible characteristic. Strains with constitutive target
modiﬁcations have high-level resistance to all
macrolides and to the related lincosamides
(including clindamycin) and streptogramin B
(MLSB compounds) and this is termed MLSB resis-
tance. If the resistance is inducible, then these
strains are only resistant to the 14- and 15-mem-
bered ring macrolides and are still susceptible to
other MLS compounds (including 16-membered
ring macrolides and clindamycin). The resistance
in these inducible phenotypes is more variable
than with the constitutive phenotype. An alterna-
tive mechanism of resistance, an efﬂux pump, was
ﬁrst recognized by Seppala et al. [4]. The efﬂux
mechanism is mediated by a mef gene and such
strains (M phenotype) only have moderate resis-
tance to 14- and 15-membered ring macrolides.
The fluctuations in resistance to macrolides in
S. pyogenes
The ﬂuctuations in the resistance to macrolides in
S. pyogenes are a feature not seen with other spe-
cies/drug combinations. In some cases this can be
associated with a rise or a reduction in the con-
sumption ofmacrolides, but this relationship is not
always evident. There are several instances where
an increase can be associated with the spread of a
serotype or clone, often also enhanced by an
increase in the use of macrolides.
In Japan, where macrolides were prescribed
very heavily, resistance was unknown prior to
1970. During the next few years the increase was
dramatic, the ﬁrst isolates (8.5%) being reported in
1971 and the level rising to 20% in 1972. By 1974–5
the level of resistance had risen to 72.3% [5]. It was
estimated in 1976 that nearly 160 tons of macro-
lides, including 50 tons of erythromycin, were
used in Japan [6]. In a study published in 1979
[5], isolates were obtained from children and all
were serotyped. There were 10 different serotypes
among these isolates, ﬁve of which were resistant
to various antibiotics, but all of the erythromycin-
resistant isolates were of a single serotype; T12.
These strains were also resistant to lincomycin,
tetracycline and chloramphenicol [5].
The authors of this study [5] commented that
‘Erythromycin and other macrolides can no longer
be considered as drug of choice in the manage-
ment of streptococcal infections in Japan’. They
suggested that regular surveillance should be car-
ried out, however, there was no ofﬁcial interven-
tion to reduce the use of macrolides and no reports
are available on their consumption. Nevertheless,
by the early 1980s resistance had fallen to 22% [7]
and is currently below 5%. In this instance, the
resistance, although inﬂuenced by the heavy use of
the drugs, was clearly linked to the spread of a
particular serotype.
A similar situation occurred in 1993 in Taiwan
where a survey revealed a high incidence of resis-
tance among isolates of S. pyogenes to erythromy-
cin and azithromycin but not to b-lactams,
vancomycin, or oﬂoxacin [8]. A total of 78 isolates
were collected over a 2-year period, tested for
susceptibility to a number of antibiotics and ser-
otyped. The precise numbers of susceptible and
resistant strains are not stated but erythromy-
cin had poor activity, with a minimum 50% in-
hibitory concentration (MIC50) of 16mg/L and
an MIC90 of >128mg/L. Clindamycin was also
inactive against some of these strains, with an
MIC90 of >32mg/L, indicating the presence of
the constitutive MLSB phenotype. There were 22
serotypes, with T12 being the most common (33
isolates); the next most common was T1 (nine
isolates). All the resistant isolates belonged to
these two serotypes, T1 or T12, with the majority
of isolates from the throat being serotype T12 (21/
24). The isolates of the T12 serotype were almost
all (28/33) highly resistant to erythromycin (MIC
>128mg/L). Two of the isolates of the T1 sero-
type had lower resistance to erythromycin (MIC
32mg/L).
A link is suggested by the authors between this
high rate of resistance and the consumption of
erythromycin in Taiwan, where apparently it is
used commonly in primary-care clinics and is
available over the counter. It is also used com-
monly in hospitals for the treatment of upper
respiratory tract infections.
In Finland in the early 1990s macrolide resist-
ance was found to be widespread but there was a
marked variation in the incidence of resistance
among the various health authorities, ranging
from 2 to 44% [9]. Overall the levels of resistance
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in S. pyogenes isolates from throat swabs showed a
marked increase from 4% in 1989 to 13% in 1990. A
highly signiﬁcant association was found between
the consumption of macrolides and the accompa-
nying level of resistance to them in S. pyogenes in
most health authority areas, but there were a few
exceptions. Following this study, a deliberate pro-
gram of intervention was undertaken [10]. Macro-
lide usage reduced from 2.40 to 1.38 deﬁned daily
doses per 1000 inhabitants per day between 1991
and 1992. The usage remained at approximately
this level for the next 3 years and a concomitant
reduction in the level of resistance was seen from a
peak of 19% in 1993 to 8.6% in 1996.
Italy is another country where resistance to
macrolides has risen markedly in the last decade.
Until 1993, local rates of resistance to erythromycin
were between 5 and 8% but from 1995 onwards
various reports indicated a sharp rise in the inci-
dence of resistance, which reached over 30% in
some studies [2]. This is in contrast to the low rates
of resistance to penicillins and macrolides seen in
S. pneumoniae, H. inﬂuenzae and M. catarrhalis in
Italy.
Even in countries where the rate of resistance is
not exceptionally high, clonal spread and/or an
association with increased use has been reported.
In Sweden, for example, 21 of 355 (5.9%) S. pyo-
genes isolates were resistant to erythromycin and
17 of these were found to be of the T12 protein
type. The spread of these was noted within two
families and a day-care center [11]. In contrast, in
France, macrolide use has remained fairly constant
for the last two decades and the level of resistance
is low, a recent survey ﬁnding only 6.8% of strains
to be resistant [12].
A survey of S. pyogenes isolates from adults and
children in Madrid, Spain, showed a dramatic
increase in resistance to macrolides from 2% in
1993 to 22.4% in 1996 [13]. Over 1300 isolates were
collected over a 3-year period in Madrid and the
overall level of resistance to erythromycin was
14.3%. Resistant strains were more frequently iso-
lated from children (144/872) than from adults
(44/434), a ﬁnding also noted by Seppala et al.
[9]. A high proportion of the resistant isolates
(>90%) were of the Mphenotype and those exam-
ined carried the mefA gene. Clindamycin resist-
ance was rare, occurring in only 18 strains, but
tetracycline resistance was more common (8.5%).
The authors also noted that the MIC of oﬂoxacin
was 4mg/L against 36 strains (2.7%).
Thus for macrolides and S. pyogenes a situation
exists where in some cases the increase in resis-
tance to macrolides can be linked to the spread of a
small number of clones, whereas in others an
association can be seen between increased con-
sumption of macrolides and a rise in resistance.
Such a simple explanation is not, however, always
evident and in some cases it is not clear why
resistance increases and may subsequently
decline.
STAPHYLOCOCCUS AUREUS—THE
PROBLEM OF MRSA
b-Lactamase production in S. aureus was evident
within a few years of the introduction of the ﬁrst
penicillins, but it was some years before strains
emerged with resistance to the new b-lactamase-
stable penicillins (methicillin, cloxacillin, oxacil-
lin). These methicillin-resistant S. aureus (MRSA)
strains have spread to many countries but estimat-
ing their incidence is difﬁcult since it varies mark-
edly even within a country and can ﬂuctuate from
time to time [14]. A major study of European
hospitals carried out between 1997 and 1999
reported varying levels of resistance from three
different areas in Spain, ranging from 9 to 34% [15].
Results from four areas in France also reported
varying levels of resistance (from 12 to 25%).
Notwithstanding these problems, it is evident that
the occurrence of MRSA is relatively low (less than
10%) in a number of countries, including Canada,
Denmark, Finland, The Netherlands, Switzerland
and Sweden [15–18]. In contrast, the rate of MRSA
is higher (between 20 and 40% of hospital strains)
in many other countries, including Belgium,
France, Italy, Portugal, Spain, UK and USA
[15,19,20]. In the Far East there are reports of an
incidence as high as between 60 and 80% in Tai-
wan [21] and in India [22].
Resistance to methicillin is often accompanied
by resistance to other antimicrobials; these can
include aminoglycosides, macrolides, tetracy-
clines, cephalosporins, carbapenems, b-lacta-
mase-inhibitor combinations, trimethoprim and
sulfonamides [14].
The spread of MRSA strains
Methicillin-resistance is an acquired drug-resis-
tance mechanism determined by the mecA gene.
This gene is not believed to be native to S. aureus
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but was probably acquired in the 1960s and has
now become integrated into the staphylococcal
DNA where it has diversiﬁed [23]. The mecA gene
codes for the production of penicillin-binding
protein 2a, which is altered in MRSA strains. A
notable feature of MRSA is the presence of epid-
emic strains which have the ability to colonize
and spread rapidly and are often the cause of
major outbreaks. These strains are frequently
multi-resistant, in contrast to non-epidemic or end-
emic strains most of which have a narrower spec-
trum of resistance and less ability to disseminate
[17].
Many large hospitals, nursing homes and
chronic-care facilities in a number of countries
have a signiﬁcant problem with MRSA, which is
now endemic. Epidemic clones can disseminate
rapidly and may even be transmitted across coun-
tries. Roman et al. [24] investigated an outbreak of
MRSA in a tertiary-care teaching center in Canada
and found that the outbreakwas caused by a single
strain. It was subsequently found that this strain
was introduced into Canada by a patient from
India and was then transmitted to two large hos-
pitals within 6weeks of the patient’s entry into
Canada. Similarly, an epidemic strain (type 1) was
found to be widespread in Belgium and in various
European countries. This strain was originally
found in France and Belgium in the 1980s and
has also been found in Germany and The Nether-
lands. Outbreaks in Dutch hospitals could be
traced to patients from France carrying the strain
[19].
Frequently a small number of epidemic MRSA
strains accounts for the majority of isolates in a
country, indicating the ability of these strains to
spread and colonize. In the Belgian study [19] the
epidemic strain type 1 accounted for 82% of the
Belgian isolates and 51% of European isolates. In
Taiwan, where the occurrence of MRSA is extre-
mely high, over 50% of isolates were typeC. The
remaining isolates were of a range of other types
[21]. In Canada, where the incidence of MRSA has
increased between 1995 and 1999, 81% of the
MRSA isolates belonged to one of four types [18].
Control of MRSA
Outbreaks of MRSA are difﬁcult to control, espe-
cially those caused by epidemic strains, but as they
can have signiﬁcant morbidity and mortality, it is
important that they are controlled or prevented.
Epidemic strains may be resistant to a wide range
of antibacterial agents, with vancomycin often
being the only antibiotic available to treat infec-
tions. Strict hospital hygiene is required to control
such outbreaks as routinemeasuresmay have little
impact. Rampling et al. [25] describe how normal
hygiene, which included isolation of the affected
patients, good hand hygiene to prevent person-to-
person transmission and staggered closure and
cleaning of the ward bays, was unable to prevent
an epidemic strain (type 16) from infecting more
patients and persisting in the hospital environ-
ment. The cleaning procedure was then changed
to include increasing the domestic cleaning time
dramatically and allocating responsibility for the
routine cleaning of shared medical equipment.
This intervention was successful in controlling
the outbreak, removing it from the environment
and reducing the numbers of patients colonized to
only three [25].
The incidence of MRSA in Denmark and Swe-
den is particularly low and this is no doubt inﬂu-
enced by the strict control measures taken in
hospitals in those countries, which prevent these
strains becoming established. In Italy, however,
control measures are generally insufﬁcient and the
incidence of MRSA is high (34.4%).
STREPTOCOCCUS PNEUMONIAE
The pneumococcus is the most common cause of
community-acquired pneumonia and can also
cause meningitis. Drug-resistant strains, many of
them resistant to a range of antimicrobials, have
spread world-wide. Resistance to penicillins is
not caused by the production of b-lactamase but
by changes to the cell wall and to the penicillin-
binding proteins. Resistance to macrolides often
accompanies resistance to b-lactams but it can
occur in a penicillin-sensitive strain. As noted
above for S. pyogenes, there are dramatic geo-
graphic differences in the incidence of resistance
to the major antimicrobials, these are illustrated in
Table 1.
In Europe the variability is particularly great,
ranging from less than 5%macrolide and penicillin
resistance in The Netherlands, to over 40% in
France (see Table 2). The greatest resistance to
macrolides is seen in France and Italy (over
40%) and the greatest overall resistance to peni-
cillin occurs in France and the Slovak Republic
(over 50%), with high levels also occurring in the
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Republic of Ireland and Greece. An interesting
feature of recent surveillance studies is that the
high-level resistance to penicillins has increased
and in many countries now exceeds the levels of
intermediate resistance.
In Italy the incidence of penicillin-resistant
pneumococci has been relatively low [2], with
approximately 4% of strains having high-level
resistance and 6–10% of strains having low-level
resistance [26]. This is in sharp contrast to the
situation with S. pyogenes described above. In a
detailed study of the types of penicillin-resistant
pneumococcal isolates the majority were found to
belong to three serotypes [27], serotype 23F (the
Spanish/USA type), serotype 9V (French/Spanish
type) and serotype 19. Two of these, 23F and 9V,
are internationally widespread clones. Over half of
these strains were also resistant to erythromycin
and tetracycline, nearly 90% were resistant to
cotrimoxazole and 41% were resistant to chloram-
phenicol. The strains with high-level resistance to
erythromycin carried the ermB gene and the strains
with low-level resistance to erythromycin carried
the mefE gene.
Macrolide resistance is often linked to penicillin
resistance (usually erm/mef) but can occur inde-
pendently. In Italy macrolide resistance reaches
40%, whereas ﬂuoroquinolone resistance is rare
but increasing. While the problem has attained
pandemic proportions, the prevalence of penicillin
resistance and multiple resistance is highly vari-
able depending on the site, e.g. The Netherlands
and India <5%; Italy 5–15%; South Africa 30–
40%; Spain and France 50%; Japan and Korea
70–80%.
What causes these differences?
It is not clear why there are such differences in the
distribution and occurrence of penicillin-resistant
strains of S. pneumoniae. The same predominant
clones are present in Italy as are circulating in
France, Spain, Japan andKorea, but their incidence
is far lower in Italy. It is difﬁcult to see any major
differences in the hygienic measures taken in Italy,
France and Spain. It is possible that the type of
selective pressure could inﬂuence resistance. The
use of less than adequate drugs such as cotrimox-
azole and some third-generation oral cephalospor-
ins may increase the possibility of resistance
developing. Oral formulations, although preferred
by both clinicians and patients, carry the risk of
poor compliance, which can compromise the value
of even the most active drug. This is especially so
with some older agents which are dosedmore than
once daily.
It is of note in this context that resistance has not
developed to ceftriaxone in pneumococci, despite
20 years of use. The drug is only available as a
parenteral, not oral, formulation, which gives
greater control over the dose given. Ceftriaxone
has been widely used in Italy where acceptance of
parenteral drugs for outpatient treatment is more
Table 1 Prevalence of penicillin resistance and macrolide
resistance among Streptococcus pneumoniae isolates from
various countries
Percentage of strains resistant to
Country
Penicillin
(intermediate)
Penicillin
(resistant) Macrolide
Brazil 13.4 3.0 3.0
Hong Kong 3.6 71.4 81.0
Japan 20.2 30.9 71.3
Mexico 36.0 17.5 28.9
Russia 3.2 0.0 3.2
Singapore 12.2 32.7 46.9
Saudi Arabia 31.2 24.7 15.6
South Africa 36.3 15.4 18.7
USA 10.8 22.1 26.0
Alexander Project 2000, Data on file—GlaxoSmithKline;
(manuscript in preparation).
Table 2 Prevalence of penicillin resistance and macrolide
resistance among Streptococcus pneumoniae isolates from
European countries
Percentage of strains resistant to
Country
Penicillin
(intermediate)
Penicillin
(resistant) Macrolide
Austria 7.6 4.8 11.4
Belgium 3.0 5.0 34.0
Czech Republic 6.1 1.0 1.0
France 12.6 40.7 47.3
Germany 5.4 1.8 4.2
Greece 16.4 15.2 18.1
Irish Republic 7.3 25.5 12.7
Italy 6.0 3.0 42.0
The Netherlands 3.2 0.0 2.4
Poland 5.5 3.5 6.2
Portugal 7.0 10.1 9.3
Slovak Republic 20.8 30.6 8.3
Switzerland 8.7 5.8 18.8
UK 4.6 14.9 18.4
Data adapted from Schito et al. [1].
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widespread than in certain other countries [28]. In
Italy, 53% of lower respiratory tract infections in
outpatients are treated with parenteral drugs, in
contrast with only 0.2% in the UK, 8% in Spain and
10% in France.
Ceftriaxone has major pharmacokinetic and
pharmacodynamic advantages, including a rapid
bactericidal activity and a long serum half-life. A
consequence of the long half-life is a sustained
minimum bactericidal concentration present in
many tissues throughout the body. A signiﬁcant
number of penicillin-resistant strains (those with
intermediate resistance) are susceptible to ceftriax-
one. This high degree of activity has been con-
ﬁrmed by the introduction of new breakpoints by
the National Committee for Clinical Laboratory
Standards for respiratory isolates of S. pneumoniae
[29].
THE IMPACT OF RESISTANCE ON
THERAPY
The effects of resistance on clinical response are
not always easy to determine and can be contro-
versial. There are, however, a few points on which
most are agreed. Penicillin resistance (MIC
4mg/L) in S. pneumoniae may not represent a
threat in non-meningeal infections if only crude
mortality rates are considered, but in meningeal
infections, strains with high-level resistance are
unlikely to respond to penicillin treatment and
the drugs are contraindicated. On the contrary,
ﬂuoroquinolone resistance may lead to clinical
failures in community-acquired pneumonia.
In a study by Varaldo et al. [30] the inﬂuence of
macrolide resistance on outcome in children with
pharyngitis caused by S. pyogenes was investi-
gated. A signiﬁcant difference in the rates of cure
between children infected with erythromycin-
resistant or erythromycin-susceptible strains was
not evident, although there was a trend towards a
lower rate of eradication (59.7% vs. 80.2%, respec-
tively), see Table 3. The authors did not distinguish
between patients infected with strains having a
low resistance and those having a high-level
resistance.
As noted above, MRSA infections generally fail
to respond to b-lactams and when the strain is an
epidemic multi-resistant one the choice of antibac-
terial agents becomes very restricted. There are
strains now circulating against which vancomycin
is the only drug that retains activity.
CONCLUSIONS
Resistance to antimicrobial agents among the spe-
cies discussed here is a global phenomenon, but
with very wide variations seen both within and
between countries. The spread of speciﬁc resistant
clones can lead to high levels of resistance in some
countries. In some instances a direct relationship
can be seen between heavy consumption of a drug
and consequent development of resistance. With
some agents a reduction in the use of a speciﬁc
group of drugs can result in a reduction in the
incidence of resistance, for example macrolides
and S. pyogenes. With other organisms, such as
S. aureus and M. catarrhalis, a reversion to suscept-
ibility is unlikely. Strict hygienic control methods
in hospitals can limit the spread of resistant clones,
for example of MRSA. The use of the most appro-
priate drugs at the appropriate dose and for an
appropriate time is the best way to prevent the
selection and spread of antibiotic resistance.
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